A bioinformatics company offers affordable genetic clinical tests for planned pregnancies.
Parents are always worried about the well-being of their children, and the fear of passing on hereditary diseases to offspring has some expecting couples reaching out to doctors ever-so-willingly. Having raised $3.3 million in venture funds, New Jersey-based biotech startup Recombine is offering affordable genetic tests that could help parents better plan for health-related issues that may affect their children.
The company’s test, called CarrierMap, analyzes blood and saliva samples for 213 genetic disorders at once, and only costs $345, a slash in price when compared to services offered by other clinical genetic testing services. Recombine genetic counselors are there to explain test results, which can be obtained one to two weeks after testing.
Recombine’s services are now being offered at 60 medical practices, and have certifications and approval from the NY Department of Health, so Recombine will not come across complications faced by 23andMe, which was briefly shut down by the FDA last year.
Alexander Bisigano, CEO of Recombine, says his company is able to keep the prices low because unlike incumbent services, who hold exclusive contracts with insurances companies and aren’t incentivized to upgrade, Recombine can explore newer technology and make changes based on consumer needs.
First and foremost, Recombine remains a clinical service company, but it tempts the interests of FirstMark Capital, Vast Ventures and other notable investors like Nat Turner and Zach Weinberg by fully leveraging Big Data technology to glean insights about genes and diseases. As the company processes anonymous data from its tests, it can decode the myriad aspects of our genome that are still not well understood, according to Matt Turck, FirstMark investor.